Beyond hydration: biological mechanisms, clinical evidence and safety of injectable skin boosters

Injectable “skin boosters” have become a cornerstone of contemporary aesthetic medicine, yet the term remains conceptually broad—often grouping agents that share an intradermal route of administration but differ substantially in biological targets, response kinetics, measurable outcomes, and risk profiles. This work provides a mechanism-based critical review of the major categories of injectable skin boosters used to improve skin quality (hydration, elasticity, texture, dermal density, and overall cutaneous vitality). The review proposes a structured framework linking mechanisms of action → objective outcome measures → expected kinetics → safety considerations, enabling a coherent interpretation of a heterogeneous literature. Hyaluronic acid (HA)–based skin boosters are discussed as hydration- and signaling-oriented ECM modulators with the strongest consistency of short-term objective endpoints (e.g., corneometry, TEWL, cutometry). Polynucleotides/PDRN are examined as multi-target regenerative modulators with biologically plausible pathways but variable clinical standardization. Calcium hydroxyapatite (CaHA) and poly-L-lactic acid (PLLA) are analyzed as biostimulatory remodelers with delayed kinetics and structural endpoints best captured by high-frequency ultrasound and/or histologic correlates when available. The manuscript also addresses collagen-based injectables (including newer cross-linked porcine collagen and emerging recombinant human collagen platforms) as ECM scaffold strategies with evolving evidence and distinct immunogenicity considerations. Finally, mesotherapy/cocktail approaches are critically discussed in light of high methodological variability and inconsistent objective endpoint support. By aligning biological rationale with measurable endpoints and time courses, this review supports evidence-informed clinical selection, realistic expectation setting, and agent-specific risk management. It also identifies key research priorities, including standardized instrumental panels, kinetics-aligned follow-up, transparent reporting of injection protocols, and head-to-head comparative trials across product categories.